BioAdaptives Targets Slice of $22B Menstrual Health Market with New Supplement
BioAdaptives, Inc. (OTC: BDPT) is targeting a slice of the $22B global menstrual health market with the launch of PluriPain®-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
PluriPain-PMS is the first of several products BioAdaptives plans to develop to support women’s health. BioAdaptives’ new products will be introduced in Q4 2023.
Edward Jacobs, M.D., CEO BioAdaptives, said, “PluriPain-PMS is designed to help manage the symptoms, especially pain and depressive mood, associated with the menstrual cycle and is based upon the addition of new ingredients derived from Traditional Chinese Medicine and Ayurvedic culture.”
Highlights
BioAdaptives’ PluriPain-PMS builds off the success of PluriPain®, a popular natural supplement for more common types of pain. The improved effects are due to dose rebalancing and the addition of natural ingredients selected for their intended synergistic features.
The global PMS and menstrual health supplements market size was valued at USD 22.6 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030.
BioAdaptives’ drug-free products are formulated to aid in breathing, pain relief, immune defense, cognition, focus, fatigue reduction, sleep, healing, anti-aging and more.
About BioAdaptives
BioAdaptives, Inc. develops and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best sources around the world and utilize proprietary methods of enhancing the bioavailability of nutrients. BioAdaptives’ current product line includes PrimiLungs™, PluriPain®, SleepEZ™, MindnMemory™ and Cell Rejuven™ for humans. The Company’s products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. BioAdaptives’ wholly owned subsidiary, LiveStock Impact, Inc. markets Canine Regen All In One™, Equine All In One™ and Equine All In One Plus™ for dogs and horses. LiveStock Impact, Inc. is also positioned to develop and market botanical drugs.
